Authored By: Sarah
21 Jun 2024

 Dry Eye Syndrome Drugs Market to grow by USD 2136.2 million between 2024-2028

According to a research report “ Dry Eye Syndrome Drugs Market” by Distribution Channel (Retail pharmacies, Hospital pharmacies, Online pharmacies) Product (OTC drugs, Prescription drugs) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 2136.2 million at a CAGR of almost 6.16% during the forecast period. In the global dry eye syndrome drugs market, the aging population represents a substantial growth opportunity. Dry eye syndrome, characterized by insufficient tear production or rapid tear evaporation, disproportionately affects older individuals. Age-related health issues, including eye disorders and diabetes, are on the rise, particularly in Asia due to its expanding geriatric demographic. North America and Europe dominate the market, driven by substantial healthcare sector investments..

Browse market data tables, figures, and in-depth TOC on “Dry Eye Syndrome Drugs Market” by Distribution Channel (Retail pharmacies, Hospital pharmacies, Online pharmacies) Product (OTC drugs, Prescription drugs) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Distribution Channel, the Retail pharmacies segment is projected to dominate the market size in 2024.

In the global dry eye syndrome drugs market, over-the-counter (OTC) medications play a significant role. These drugs, which do not require a prescription, are primarily utilized for self-medication and symptom management. The OTC segment encompasses a range of products designed to alleviate dryness, irritation, and discomfort associated with dry eye syndrome. Notable OTC drugs for dry eye syndrome include artificial tears, which mimic natural tears and offer temporary relief by lubricating the eyes.

By Product, OTC drugs  segment is expected to hold the largest market size for the year 2024.

In the retail pharmacy sector, dry eye syndrome drugs experience substantial demand due to their role in providing immediate access to essential OTC and prescription medications for patients. Independent pharmacies, chain pharmacies, and drugstore retailers all contribute to this segment by stocking a diverse range of dry eye treatments, including artificial tears, ointments, gels, and prescription medications. Pharmacists offer valuable consultations, ensuring patients make informed decisions on product selection and usage. This personalized approach caters to consumers seeking in-person assistance and customized recommendations.

North America is forecasted to hold the largest market size by region in 2024.

In the Dry Eye Syndrome Drugs Market, businesses focus on developing and marketing innovative solutions to address the unmet needs of patients. Key products include artificial tears, anti-inflammatory drugs, and tear stimulants. Companies strive to improve product efficacy, safety, and patient compliance, while navigating regulatory requirements and competition. Market growth is driven by increasing prevalence, aging populations, and technological advancements.

The Dry Eye Syndrome Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • AFT Pharmaceuticals Ltd.
  • Akorn Operating Co LLC
  • Bausch Health Companies Inc.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • I MED Pharma Inc.
  • Johnson and Johnson Services Inc.
  • Laboratoires Thea
  • Mitotech SA
  • Novaliq GmbH
  • Novartis AG
  • Oasis Medical Inc.
  • Otsuka Holdings Co. Ltd.
  • Santen Pharmaceutical Co. Ltd.
  • Sentiss Pharma Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Visufarma
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

In the realm of ocular health, the Dry Eye Syndrome (DES) market encompasses a significant segment of clinical care. This condition, characterized by discomfort, irritation, and visual disturbances due to insufficient tears or poor tear quality, affects various demographics, including the geriatric population and those with rheumatic conditions or diabetes. The development of DES drugs involves rigorous clinical trials and regulatory procedures to ensure drug approval and safety. Key players in this market include drug manufacturers producing advanced therapies such as CEQUA therapy drug, which utilizes nanodroplet technology for improved efficacy. Alternative therapies, like acupuncture and nutritional supplements, also hold potential in addressing DES. Optometrists, ophthalmologists, and eye clinics provide essential clinical care for patients, while private practices offer personalized treatment plans. Autoimmune disorders and hormonal changes can contribute to DES, necessitating ongoing research and innovation in the field. Eye care centers remain dedicated to providing comprehensive solutions for patients, ensuring they receive the best possible care for their dry eye symptoms.

Market Research Overview

In the realm of ophthalmic treatments, the Dry Eye Syndrome (DES) market is witnessing significant advancements, particularly in the development of prescription disease drugs. Patients suffering from Meibomian gland dysfunction, a primary cause of DES, are in search of effective treatments. Immunoglobulin drops, such as Selagine, are emerging as potential solutions, offering reversible action and improved systemic absorption. The patient pool for DES is vast, encompassing individuals with various chronic health conditions, including rheumatic diseases, diabetes, thyroid disease, and vitamin A deficiency. Advanced emerging drugs, like CEQUA therapy drug, are undergoing Phase 3 clinical trials for approval, aiming to address the regulatory burden and investment cost associated with diagnosis and treatment. Nanodroplet technology and microencapsulation are innovative approaches in the field of healthcare infrastructure, enabling the development of more effective and patient-friendly ocular condition treatments. The geriatric population, with hormonal changes and high screen time, is a significant focus for drug manufacturers. Alternative therapies, such as acupuncture and nutritional supplements, are also gaining popularity in the eye care sector. Optometrists, ophthalmologists, and eye clinics are key players in the DES market, providing clinical care and advanced therapies to patients. Autoimmune disorders, such as lupus, and dry eye disease are major indications driving the market growth. The regulatory procedures for drug approval and the increasing demand for healing treatments further fuel the market's expansion.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio